Literature DB >> 31405608

New Perspectives in Latent Tuberculosis Infection.

Miguel Arias-Guillén1, Patricio Escalante2, Juan José Palacios Gutiérrez3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31405608      PMCID： PMC8878434          DOI： 10.1016/j.arbres.2019.07.009

Source DB:  PubMed          Journal:  Arch Bronconeumol (Engl Ed)        ISSN： 2173-5751


× No keyword cloud information.
  14 in total

1.  A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes.

Authors:  Roshni Roy Chowdhury; Francesco Vallania; Qianting Yang; Cesar Joel Lopez Angel; Fatoumatta Darboe; Adam Penn-Nicholson; Virginie Rozot; Elisa Nemes; Stephanus T Malherbe; Katharina Ronacher; Gerhard Walzl; Willem Hanekom; Mark M Davis; Jill Winter; Xinchun Chen; Thomas J Scriba; Purvesh Khatri; Yueh-Hsiu Chien
Journal:  Nature       Date:  2018-08-22       Impact factor: 49.962

2.  Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.

Authors:  Laith J Abu-Raddad; Lorenzo Sabatelli; Jerusha T Achterberg; Jonathan D Sugimoto; Ira M Longini; Christopher Dye; M Elizabeth Halloran
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

3.  Three months of rifapentine and isoniazid for latent tuberculosis infection.

Authors:  Timothy R Sterling; M Elsa Villarino; Andrey S Borisov; Nong Shang; Fred Gordin; Erin Bliven-Sizemore; Judith Hackman; Carol Dukes Hamilton; Dick Menzies; Amy Kerrigan; Stephen E Weis; Marc Weiner; Diane Wing; Marcus B Conde; Lorna Bozeman; C Robert Horsburgh; Richard E Chaisson
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

Review 4.  Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Leila C Kahwati; Cynthia Feltner; Michael Halpern; Carol L Woodell; Erin Boland; Halle R Amick; Rachel Palmieri Weber; Daniel E Jonas
Journal:  JAMA       Date:  2016-09-06       Impact factor: 56.272

5.  One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.

Authors:  Susan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A Jean Juste; Javier R Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V Fletcher; Eric Nuermberger; Richard E Chaisson
Journal:  N Engl J Med       Date:  2019-03-14       Impact factor: 91.245

6.  Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.

Authors:  Elitza S Theel; Heather Hilgart; Margaret Breen-Lyles; Kevin McCoy; Rhiannon Flury; Laura E Breeher; John Wilson; Irene G Sia; Jennifer A Whitaker; Jeremy Clain; Timothy R Aksamit; Patricio Escalante
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

Review 7.  Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease.

Authors:  Delia Goletti; Meng-Rui Lee; Jann-Yuan Wang; Nicholas Walter; Tom H M Ottenhoff
Journal:  Respirology       Date:  2018-02-18       Impact factor: 6.424

Review 8.  Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis.

Authors:  Elisa Petruccioli; Thomas J Scriba; Linda Petrone; Mark Hatherill; Daniela M Cirillo; Simone A Joosten; Tom H Ottenhoff; Claudia M Denkinger; Delia Goletti
Journal:  Eur Respir J       Date:  2016-11-11       Impact factor: 16.671

9.  Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.

Authors:  Elisa Nemes; Hennie Geldenhuys; Virginie Rozot; Kathryn T Rutkowski; Frances Ratangee; Nicole Bilek; Simbarashe Mabwe; Lebohang Makhethe; Mzwandile Erasmus; Asma Toefy; Humphrey Mulenga; Willem A Hanekom; Steven G Self; Linda-Gail Bekker; Robert Ryall; Sanjay Gurunathan; Carlos A DiazGranados; Peter Andersen; Ingrid Kromann; Thomas Evans; Ruth D Ellis; Bernard Landry; David A Hokey; Robert Hopkins; Ann M Ginsberg; Thomas J Scriba; Mark Hatherill
Journal:  N Engl J Med       Date:  2018-07-12       Impact factor: 91.245

10.  Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Authors:  Olivier Van Der Meeren; Mark Hatherill; Videlis Nduba; Robert J Wilkinson; Monde Muyoyeta; Elana Van Brakel; Helen M Ayles; German Henostroza; Friedrich Thienemann; Thomas J Scriba; Andreas Diacon; Gretta L Blatner; Marie-Ange Demoitié; Michele Tameris; Mookho Malahleha; James C Innes; Elizabeth Hellström; Neil Martinson; Tina Singh; Elaine J Akite; Aisha Khatoon Azam; Anne Bollaerts; Ann M Ginsberg; Thomas G Evans; Paul Gillard; Dereck R Tait
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.